-+ 0.00%
-+ 0.00%
-+ 0.00%

YKYY033 injection, a subsidiary of Yuekang Pharmaceutical (688658.SH), was approved for clinical trials with new indications

Zhitongcaijing·07/21/2026 09:33:07
Listen to the news

Zhitong Finance App News, Yuekang Pharmaceutical (688658.SH) issued an announcement. The company's subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently obtained the approval and issuance of the “Drug Clinical Trial Approval Notice” on the new indications of YKYY033 injections by the State Drug Administration. The company will carry out phase I clinical trials of this product.

The drug's application indications are: for the treatment of deep venous thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT; for patients with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke and systemic embolism; for patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) to reduce the risk of major cardiovascular events; prevention of major thrombotic vascular events in patients with end-stage renal disease (ESRD); for the treatment and prevention of secondary tumor-associated venous embolism (VTE).